ライフサイエンスコーパス: esmolol

1 ttributed to the anti-inflammatory effect of esmolol.

2 st and after administration of dobutamine or esmolol.

3 obutamine and decreased with the infusion of esmolol.

4 ntly higher with sotalol than they were with esmolol.

5 icantly higher with sotalol than it was with esmolol.

6 ent manner; such an effect was not seen with esmolol.

7 tropic modulation stages with dobutamine and esmolol.

8 re was induced with a continuous infusion of esmolol.

9 ration of the beta-adrenoreceptor antagonist esmolol (1 mg kg(-1)) also attenuated the effect of vaga

10 0/min, 40% inspiratory time) under baseline, esmolol (2 mg/min), dobutamine infusions (5 microg/kg/mi

11 ld-type mice survived challenge with 4 mg/kg esmolol, 6 of 8 compound Ero1l and Ero1lb mutant mice su

12 on and that the short-acting beta-antagonist esmolol administered at reperfusion would protect agains

13 is was more pronounced after RFA than during esmolol administration (23 +/- 11 mm vs. 7 +/- 5 mm, res

14 ated animals were significantly better after esmolol administration and duration of survival was sign

15 The difference in caudal shift seen after esmolol administration and following SN modification sug

16 were obtained at baseline and 24 hours after esmolol administration.

17 elastance during contractility modulation by esmolol and dobutamine and assessed during preload reduc

18 elastance during contractility modulation by esmolol and dobutamine and during preload reduction and

19 change and peak ejection rate decreased with esmolol and increased with dobutamine.

20 created a model of global LV dysfunction by esmolol and phenylephrine infusion in six dogs, initiall

21 mean time of contraction were prolonged with esmolol and shortened with dobutamine.

22 tions and after sequential administration of esmolol and sotalol.

23 ment: 6 left stellate ganglionic blockade, 7 esmolol, and 14 propranolol.

24 phen, as well as alpha-2 agonists, ketamine, esmolol, and nonpharmacologic approaches (e.g., transcut

25 Esmolol before reperfusion improved return of spontaneou

26 Esmolol did not improve orthostatic tolerance or hemodyn

27 Without esmolol, dobutamine stress induced myocardial ischemia w

28 Esmolol, dobutamine, and atropine were used to track var

29 le animals were treated with a beta-blocker, esmolol, during a severe hypercapnic acidosis challenge.

30 t rates were achieved in all patients in the esmolol group compared with those in the control group.

31 0.11 mug/kg/min (IQR, -0.46 to 0.02) for the esmolol group vs -0.01 mug/kg/min (IQR, -0.2 to 0.44) fo

32 hours was -28/min (IQR, -37 to -21) for the esmolol group vs -6/min (95% CI, -14 to 0) for the contr

33 Twenty-eight day mortality was 49.4% in the esmolol group vs 80.5% in the control group (adjusted ha

34 Fluid requirements were reduced in the esmolol group: median AUC was 3975 mL/24 h (IQR, 3663 to

35 Phenylephrine, but not esmolol, improves orthostatic tolerance and hemodynamics

36 als were randomized to receive 300 microg/kg esmolol in a volume of 200 microL or an equivalent volum

37 ephrine, and a beta-1 adrenergic antagonist, esmolol, in 14 patients with POTS aged 13 to 19 years.

38 gnitude lead was significantly reduced after esmolol infusion (P<0.001), and the number of positive T

39 Esmolol infusion decreased both pulse pressure variation

40 trated that heart rate control by a titrated esmolol infusion in septic shock patients was associated

41 Esmolol infusion increased cardiac contractility and res

42 han or equal to 65 mm Hg received a titrated esmolol infusion to maintain heart rate less than 95 bea

43 Esmolol infusion was also associated with an up-regulati

44 sitropic state was changed by dobutamine and esmolol infusion.

45 sitropic state was changed by dobutamine and esmolol infusion.

46 fusion up to 1 h, followed by dobutamine and esmolol infusions.

47 Esmolol led to a decrease in IVA and dP/dt(max).

48 Study 1: Esmolol led to a decrease in IVA and Emax (P<0.03 and <0

49 l experimental stages (baseline, dobutamine, esmolol) led to a significant decrease (P < or = 0.01) i

50 tile amplitude, force, and frequency whereas esmolol markedly decreased these contractile properties.

51 Animals received 1.0 mg/kg esmolol (n=8) or saline (n=8) intravenously at the start

52 s measured again after sympathetic blockade (esmolol, n=20), parasympathetic blockade (atropine, n=20

53 prusside, diazoxide, hydralazine, labetalol, esmolol, nicardipine, nifedipine, enalaprilat, and minox

54 allocated to the following groups: control, esmolol, norepinephrine (started at 18 hr after the surg

55 Currently, the effects of esmolol on in vivo cardiac function and on vascular func

56 e the effects of the beta1-selective blocker esmolol on myocardial and vascular function in peritonit

57 Opposing significant decreases occurred with esmolol: peak systolic velocity of 4.46 +/- 0.94 to 2.31

58 Esmolol prevented dobutamine-induced ischemia (lactate p

59 nt relation between APD and LV (+)dP/dt with esmolol (r = 0.27, p = NS).

60 hmic agents (i.e., adenosine, verapamil, and esmolol, respectively) until the arrhythmia was terminat

61 riuretic peptide, exenatide, metoprolol, and esmolol) stand unchallenged to date in reducing infarct

62 ne (started at 18 hr after the surgery), and esmolol (started at 4 hr after the surgery) + norepineph

63 patients to receive a continuous infusion of esmolol titrated to maintain heart rate between 80/min a

64 Esmolol-treated animals required a significantly smaller

65 Each of the esmolol-treated but only five of nine placebo-treated an

66 tain heart rate between 80/min and 94/min by esmolol treatment over a 96-hour period.

67 <0.05]) and decreased with administration of esmolol (v(endo) 1.4+/-0.2 cm/s [P<0.05]; SR 6+/-1 s(-1)

68 patients in septic shock, open-label use of esmolol vs standard care was associated with reductions

69 For arterial lactatemia, median AUC for esmolol was -0.1 mmol/L (IQR, -0.6 to 0.2) vs 0.1 mmol/L

70 s the left ventricular stroke work index for esmolol was 3 mL/m2 (IQR, 0 to 8) vs 1 mL/m2 for the con

71 For stroke volume index, the median AUC for esmolol was 4 mL/m2 (IQR, -1 to 10) vs 1 mL/m2 for the c

72 ge in activation after the administration of esmolol was also assessed and compared to the shift docu

73 iest activation site after administration of esmolol was compared with the shift after RFA.

74 c abnormalities elicited with this infusion, esmolol was infused at 50 micrograms/kg body weight per

75 g beta1-selective adrenergic blocking agent, esmolol, was administrated during cardiopulmonary resusc

76 and caval occlusion, whereas dobutamine and esmolol were used to change LV and LA relaxation.

77 mine infusion than with that performed after esmolol with atropine added at the maximal dobutamine do

78 shock using the beta-1 adrenoceptor blocker, esmolol, with specific focus on systemic hemodynamics an